Avila Therapeutics
About
Science
Pipeline
News
Careers
Contact
Transforming the treatment of human disease through protein silencing

Avila Therapeutics™
Covalent Drugs: Bonding to Targets, Silencing the Disease

Avila Therapeutics will treat human diseases using a remarkably powerful therapeutic approach called ‘protein silencing.’ Using a proprietary platform, Avila generates covalent drugs that strongly and resiliently bond to specific disease-causing proteins, thereby “silencing” them and eradicating the corresponding disease. Avila’s novel covalent drugs have the potential to improve patient outcomes in a fundamentally new way, and Avila is rapidly developing these therapies for a number of diseases, including viral infections, cancers and autoimmune diseases.

12/08/08
Avila Comes Out of Stealth to Talk Bonds, Covalent Bonds

12/07/08
Avila Presents Data on Novel Btk Inhibitor, AVL-101, for B Cell Malignancies at the Annual Meeting of the American Society of Hematology

12/05/08
Avila Therapeutics Appoints Daniel S. Lynch as Executive Chairman